Judge Says FDA Authority Preempts Celebrex Failure-to-Warn Claims



DOCUMENTS
  • Memorandum & Order


SAN FRANCISCO - The judge overseeing the federal Bextra/Celebrex MDL has dismissed as preempted purchaser plaintiffs' failure-to-warn claims against Pfizer Inc. concerning the cardiovascular risks of Celebrex, finding that the claims conflict with the FDA's determination of what warnings are substantiated by the scientific evidence. In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL No. 1699 (N.D. Calif.).

In the same Aug. 16 order, Judge Charles R. Breyer of the U.S. District Court for the Northern District of California denied Pfizer's motion to dismiss plaintiffs' false advertising claims on conflict preemption grounds. The judge stated that …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Water Contamination Litigation Presented by EisnerAmper

May 06, 2025

MORE DETAILS



HarrisMartin's Data Breach Litigation Conference

March 26, 2025 - Charlotte, NC
Omni Charlotte Hotel

MORE DETAILS